Trial Profile
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Dexamethasone; Folinic acid; Folinic acid; Hydrocortisone sodium succinate; Mercaptopurine; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Pegaspargase; Pegaspargase; Prednisolone; Prednisolone; Tioguanine; Tioguanine; Vincristine
- Indications Acute biphenotypic leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 26 Sep 2023 Planned End Date changed from 9 Jun 2024 to 22 Sep 2024.
- 23 Jun 2023 Planned End Date changed from 9 Jun 2023 to 9 Jun 2024.
- 13 Dec 2022 Results (data cutoff (06/30/2022) assessing the survival outcomes of azacitidine as epigenetic priming for chemotherapy in infants less than 1 year of age with KMT2A-rearranged acute lymphoblastic leukemia, presented at the 64th American Society of Hematology Annual Meeting and Exposition.